

JUL 13 2005

Serial No. 09/980,516

Supplemental Response After Final

Amendments to the Claims

Please amend the claims as follows:

1. (currently amended) A formulation which comprises a ligand capable of binding to a HLA-DR protein present at the surface of an infectious agent and at the membrane surface of a cell, said ligand being coupled to a lipid-comprising vesicle.
2. (previously presented) The formulation according to claim 1 wherein said lipid-comprising vesicle is a liposome.
3. (previously presented) The formulation according to claim 2 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
4. (previously presented) The formulation according to claim 3, wherein said liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.
5. (previously presented) The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight between about 500 and 5000 daltons.
6. (previously presented) The formulation according to claim 3, wherein the molar ratio is 10:3.
7. (previously presented) The formulation according to claim 4, wherein said liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.
8. (previously presented) The formulation according to claim 2, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol in a

Serial No. 09/980,516

Supplemental Response After Final

molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

9. (previously presented) The formulation according to claim 2, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol:dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

10. (previously presented) The formulation according to claim 1, further comprising an additional ligand to one or more proteins selected from a histocompatibility complex protein, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD1 (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and B 2-microglobulin.

11. (previously presented) The formulation according to claim 1, wherein said ligand is an antibody molecule selected from a whole antibody and an antibody fragment.

12. (previously presented) The formulation according to claim 1, which comprises a drug effective against a disease or against the symptoms of a disease caused by an infectious agent.

13. (currently amended) The formulation according to claim 1, wherein said HLA-DR protein is present at the membrane surface of expressed in a lymphoid cell or a cell of the reticuloendothelial system.

14. (currently amended) The formulation according to claim 12, wherein said HLA-DR protein is present at the membrane surface of expressed in a lymphoid cell or a cell of the reticuloendothelial system.

Serial No. 09/980,516

Supplemental Response After Final

15. (previously presented) The formulation according to claim 13, wherein said HLA-DR protein is acquired by HIV.
16. (previously presented) The formulation according to claim 14, wherein said HLA-DR protein is acquired by HIV.
17. (previously presented) The formulation according to claim 13, wherein said ligand further comprises an additional ligand to one or more of CD4, MHC-I and CD54 proteins.
18. (previously presented) The formulation according to claim 14, further comprising an additional ligand to one or more of CD4, MHC-I and CD54 proteins.
19. (previously presented) The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, ritonavir, nelfinavir, ganciclovir, foscarnet, ribavirin, amphotericin B and nystatin A.
20. (previously presented) The formulation according to claim 1, wherein said ligand is an anti-Fab' antibody fragment directed against a HLA-DR protein.
- 21 - 23. (canceled)